CORRECTED-BRIEF-Sanofi’s Venglustat Granted Priority Review By The FDA For Treatment Of GD3 (May 28)

Adjusts the headline and bullets in a brief from May 28 to correct abbreviation error of a disease the medicine is meant to treat

May 29 (Reuters) - Sanofi SA SASY.PA:

  • FDA GRANTS PRIORITY REVIEW TO VENGLUSTAT NDA

  • TO PURSUE ADDITIONAL GLOBAL REGULATORY FILINGS FOR VENGLUSTAT IN 2026

  • VENGLUSTAT RECEIVED BREAKTHROUGH, FAST TRACK, AND ORPHAN DRUG DESIGNATIONS FOR GD3

  • IF APPROVED, VENGLUSTAT WOULD BECOME THE FIRST TREATMENT AVAILABLE IN THE UNITED STATES FOR THE PROGRESSIVE NEUROLOGICAL SYMPTOMS ASSOCIATED WITH GD3

Source text

Further company coverage: SASY.PA


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.